Q-Pharm, one of Australia’s leading early-phase clinical research organisations, has announced the appointment of Dr Tufail Syed as new CEO.
Q-Pharm was founded in 2002 as an early-stage clinical trial company. It has conducted more than 400 clinical trials in its facilities located at Brisbane’s QIMR Berghofer Medical Research Institute.
Dr Syed has 17 years of clinical research experience gained in academia, large pharmaceutical companies and global clinical research organisations.
Most recently, he held the role of regional head of Global Testing Services for the Asia-Pacific at Covance. Prior to that, Dr Syed held executive and senior leadership roles at Medpace and Eli Lilly.
He trained as a physician in India before relocating to the US, where he did further training and worked as a medical researcher. He received an MBA from Rutgers Business School in New Jersey.
“Q-Pharm has proved itself to be a reliable partner to the clinical research enterprise over the last 15 years, through its high quality, safety, and operational excellence,” said Dr Syed.
“I am delighted to join a best-in-class clinical research team that is dedicated to providing exceptional services to our clients and improving lives through clinical research.”
The chairman of the Q-Pharm board, Professor Frank Gannon, said Dr Syed brought a rich and diverse set of skills, knowledge and experience to the role.
“I am delighted to welcome Tufail Syed as we enter a new and ambitious phase of the company,” said Professor Gannon.
“Under his leadership, Q-Pharm will maintain its focus on reliability and quality, while expanding our activities to new markets and offerings.
“Dr Syed brings a great combination of skills and experience, which will ensure that these goals are reached.”
The Q-Pharm board thanked interim CEO Michael Creevey for his support and leadership during the transition period prior to Dr Syed’s appointment.